Idarubicin appears equivalent to dose-intense daunorubicin for remission induction in patients with acute myeloid leukemia

Steven Trifilio; Zheng Zhou; Jayesh Mehta; Colleen Czerniak; Judy Pi; Deborah Greenberg; Molly Koslosky; Mihaela Pantiru; Jessica Altman

doi:10.1016/j.leukres.2013.04.009

Idarubicin appears equivalent to dose-intense daunorubicin for remission induction in patients with acute myeloid leukemia

Steven Trifilio^*, Zheng Zhou, Jayesh Mehta, Colleen Czerniak, Judy Pi, Deborah Greenberg, Molly Koslosky, Mihaela Pantiru, Jessica Altman

^*Corresponding author for this work

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

Daunorubicin has historically been considered the anthracycline of choice at many cancer centers for the treatment of acute myeloid leukemia (AML). Drug shortages have required the substitution of daunorubicin with idarubicin. Randomized studies have shown idarubicin (10-12mg/m²) to be comparable or superior to standard dose daunorubicin (45-60mg/m²) for achieving complete remission (CR). Whether these results can be extrapolated to dose-intense daunorubicin (90mg/m²), recently shown to improve CR rates when compared to standard daunorubicin doses remains uncertain. This observational study was conducted at Northwestern Memorial Hospital (NMH) to compare CR rates. The results suggest idarubicin is equivalent to daunorubicin, and for some subsets of patients, idarubicin may have superior CR rates.

Original language	English (US)
Pages (from-to)	868-871
Number of pages	4
Journal	Leukemia Research
Volume	37
Issue number	8
DOIs	https://doi.org/10.1016/j.leukres.2013.04.009
State	Published - Aug 2013

Keywords

Acute leukemia
Daunorubicin
Idarubicin

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.leukres.2013.04.009

Cite this

@article{4d4a10c8dbde4a8aab90136bdd765484,

title = "Idarubicin appears equivalent to dose-intense daunorubicin for remission induction in patients with acute myeloid leukemia",

abstract = "Daunorubicin has historically been considered the anthracycline of choice at many cancer centers for the treatment of acute myeloid leukemia (AML). Drug shortages have required the substitution of daunorubicin with idarubicin. Randomized studies have shown idarubicin (10-12mg/m2) to be comparable or superior to standard dose daunorubicin (45-60mg/m2) for achieving complete remission (CR). Whether these results can be extrapolated to dose-intense daunorubicin (90mg/m2), recently shown to improve CR rates when compared to standard daunorubicin doses remains uncertain. This observational study was conducted at Northwestern Memorial Hospital (NMH) to compare CR rates. The results suggest idarubicin is equivalent to daunorubicin, and for some subsets of patients, idarubicin may have superior CR rates.",

keywords = "Acute leukemia, Daunorubicin, Idarubicin",

author = "Steven Trifilio and Zheng Zhou and Jayesh Mehta and Colleen Czerniak and Judy Pi and Deborah Greenberg and Molly Koslosky and Mihaela Pantiru and Jessica Altman",

year = "2013",

month = aug,

doi = "10.1016/j.leukres.2013.04.009",

language = "English (US)",

volume = "37",

pages = "868--871",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Ltd",

number = "8",

}

TY - JOUR

T1 - Idarubicin appears equivalent to dose-intense daunorubicin for remission induction in patients with acute myeloid leukemia

AU - Trifilio, Steven

AU - Zhou, Zheng

AU - Mehta, Jayesh

AU - Czerniak, Colleen

AU - Pi, Judy

AU - Greenberg, Deborah

AU - Koslosky, Molly

AU - Pantiru, Mihaela

AU - Altman, Jessica

PY - 2013/8

Y1 - 2013/8

N2 - Daunorubicin has historically been considered the anthracycline of choice at many cancer centers for the treatment of acute myeloid leukemia (AML). Drug shortages have required the substitution of daunorubicin with idarubicin. Randomized studies have shown idarubicin (10-12mg/m2) to be comparable or superior to standard dose daunorubicin (45-60mg/m2) for achieving complete remission (CR). Whether these results can be extrapolated to dose-intense daunorubicin (90mg/m2), recently shown to improve CR rates when compared to standard daunorubicin doses remains uncertain. This observational study was conducted at Northwestern Memorial Hospital (NMH) to compare CR rates. The results suggest idarubicin is equivalent to daunorubicin, and for some subsets of patients, idarubicin may have superior CR rates.

AB - Daunorubicin has historically been considered the anthracycline of choice at many cancer centers for the treatment of acute myeloid leukemia (AML). Drug shortages have required the substitution of daunorubicin with idarubicin. Randomized studies have shown idarubicin (10-12mg/m2) to be comparable or superior to standard dose daunorubicin (45-60mg/m2) for achieving complete remission (CR). Whether these results can be extrapolated to dose-intense daunorubicin (90mg/m2), recently shown to improve CR rates when compared to standard daunorubicin doses remains uncertain. This observational study was conducted at Northwestern Memorial Hospital (NMH) to compare CR rates. The results suggest idarubicin is equivalent to daunorubicin, and for some subsets of patients, idarubicin may have superior CR rates.

KW - Acute leukemia

KW - Daunorubicin

KW - Idarubicin

UR - http://www.scopus.com/inward/record.url?scp=84879788734&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879788734&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2013.04.009

DO - 10.1016/j.leukres.2013.04.009

M3 - Article

C2 - 23726414

AN - SCOPUS:84879788734

SN - 0145-2126

VL - 37

SP - 868

EP - 871

JO - Leukemia Research

JF - Leukemia Research

IS - 8

ER -

Idarubicin appears equivalent to dose-intense daunorubicin for remission induction in patients with acute myeloid leukemia

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this